Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.

Disc Medicine, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

WATERTOWN, MASS., JULY 14, 2025 (GLOBE NEWSWIRE) -- DISC MEDICINE, INC. (NASDAQ:IRON), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF NOVEL TREATMENTS FOR PATIENTS SUFFERING FROM SERIOUS HEMATOLOGIC DISEASES, TODAY ANNOUNCED THE APPOINTMENT OF NADIM AHMED TO ITS BOARD OF DIRECTORS. MR. AHMED IS CURRENTLY THE PRESIDENT AND CHIEF EXECUTIVE OFFICER OF CULLINAN THERAPEUTICS.

DISC MEDICINE APPOINTS NADIM AHMED TO ITS BOARD OF DIRECTORS

WATERTOWN, MASS., JUNE 12, 2025 (GLOBE NEWSWIRE) -- DISC MEDICINE, INC. (NASDAQ:IRON), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF NOVEL TREATMENTS FOR PATIENTS SUFFERING FROM SERIOUS HEMATOLOGIC DISEASES, TODAY SPOTLIGHTS 5 POSTERS PRESENTED AT THE EHA 2025 ANNUAL MEETING IN MILAN, ITALY. THIS YEAR'S PRESENTATIONS INCLUDED DATA FROM HELIOS, AN ONGOING OPEN-LABEL EXTENSION STUDY OF BITOPERTIN IN EPP, WHICH SHOWED FAVORABLE LONG-TERM EFFICACY AND SAFETY WITH SUSTAINED PROTOPORPHYRIN IX (PPIX) REDUCTIONS, IMPROVEMENT IN QUALITY OF LIFE, AND IMPROVED LIVER BIOMARKERS. DISC IS ADVANCING DEVELOPMENT AND REGISTRATIONAL ACTIVITIES FOR BITOPERTIN IN EPP, WITH PLANS TO SUBMIT AN NDA IN H2 2025. THE COMPANY HAS INITIATED APOLLO, A CONFIRMATORY CLINICAL TRIAL OF BITOPERTIN IN ADULTS AND ADOLESCENTS WITH EPP. DISC RECENTLY LAUNCHED A CAMPAIGN TO RAISE AWARENESS OF EPP AMONG PHYSICIANS, PATIENTS, AND CAREGIVERS WITH EMPHASIS ON THE CAUSATIVE ROLE OF PPIX ACCUMULATION IN THE DISEASE. LEARN MORE AT PPIXISWHY.COM.

DISC MEDICINE PRESENTS POSITIVE CLINICAL DATA UPDATES ACROSS PORTFOLIO AT THE EUROPEAN HEMATOLOGY ASSOCIATION (EHA) 2025 ANNUAL CONGRESS

WATERTOWN, MASS., MAY 28, 2025 (GLOBE NEWSWIRE) -- DISC MEDICINE, INC. (NASDAQ:IRON), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF NOVEL TREATMENTS FOR PATIENTS SUFFERING FROM SERIOUS HEMATOLOGIC DISEASES, ANNOUNCED TODAY THAT COMPANY MANAGEMENT WILL PARTICIPATE IN FIRESIDE CHATS AT TWO UPCOMING INVESTOR CONFERENCES:

DISC MEDICINE TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

WATERTOWN, MASS., MAY 14, 2025 (GLOBE NEWSWIRE) -- DISC MEDICINE, INC. (NASDAQ:IRON), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF NOVEL TREATMENTS FOR PATIENTS SUFFERING FROM SERIOUS HEMATOLOGIC DISEASES, TODAY ANNOUNCED THAT IT WILL PRESENT DATA FROM MULTIPLE PROGRAMS IN ITS HEMATOLOGY PORTFOLIO AT THE UPCOMING EUROPEAN HEMATOLOGY ASSOCIATION (EHA) 2025 CONGRESS, WHICH WILL BE HELD IN MILAN, ITALY ON JUNE 12-15, 2025.

DISC MEDICINE ANNOUNCES MULTIPLE PRESENTATIONS ACROSS PORTFOLIO AT THE EUROPEAN HEMATOLOGY ASSOCIATION (EHA) 2025 CONGRESS

WATERTOWN, MASS., MAY 07, 2025 (GLOBE NEWSWIRE) -- DISC MEDICINE, INC. (NASDAQ:IRON), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF NOVEL TREATMENTS FOR PATIENTS SUFFERING FROM SERIOUS HEMATOLOGIC DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025, AND PROVIDED A RECAP OF RECENT PROGRAM AND CORPORATE DEVELOPMENTS.

DISC MEDICINE REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

WATERTOWN, MASS., FEB. 27, 2025 (GLOBE NEWSWIRE) -- DISC MEDICINE, INC. (NASDAQ:IRON), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF NOVEL TREATMENTS FOR PATIENTS SUFFERING FROM SERIOUS HEMATOLOGIC DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2024, AND PROVIDED A RECAP OF RECENT PROGRAM AND CORPORATE DEVELOPMENTS.

DISC MEDICINE REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

WATERTOWN, MASS., FEB. 26, 2025 (GLOBE NEWSWIRE) -- DISC MEDICINE, INC. (NASDAQ:IRON), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF NOVEL TREATMENTS FOR PATIENTS SUFFERING FROM SERIOUS HEMATOLOGIC DISEASES, ANNOUNCED TODAY THAT COMPANY MANAGEMENT WILL PRESENT AT THREE UPCOMING INVESTOR CONFERENCES:

SAN FRANCISCO--(BUSINESS WIRE)-- #FORTUNE500--CHEF MORIMOTO LAUNCHES NEW EXCLUSIVE FOOD COLLABORATION WITH WILLIAMS SONOMA.

WILLIAMS SONOMA LAUNCHES NEW COLLABORATION WITH IRON CHEF MASAHARU MORIMOTO

WATERTOWN, MASS., JAN. 22, 2025 (GLOBE NEWSWIRE) -- DISC MEDICINE, INC. (NASDAQ: IRON) (DISC), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF NOVEL TREATMENTS FOR PATIENTS SUFFERING FROM SERIOUS HEMATOLOGIC DISEASES, TODAY ANNOUNCED THE PRICING OF ITS UPSIZED UNDERWRITTEN OFFERING OF SHARES OF ITS COMMON STOCK AND, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS THAT SO CHOOSE, PRE-FUNDED WARRANTS TO PURCHASE SHARES OF ITS COMMON STOCK. DISC IS SELLING 3,918,182 SHARES OF COMMON STOCK AND PRE-FUNDED WARRANTS TO PURCHASE 181,818 SHARES OF COMMON STOCK IN THE OFFERING. THE SHARES OF COMMON STOCK ARE BEING SOLD AT AN OFFERING PRICE OF $55.00 PER SHARE, AND THE PRE-FUNDED WARRANTS ARE BEING SOLD AT AN OFFERING PRICE OF $54.9999 PER PRE-FUNDED WARRANT, WHICH REPRESENTS THE PER SHARE OFFERING PRICE FOR THE COMMON STOCK LESS THE $0.0001 PER SHARE EXERCISE PRICE FOR EACH SUCH PRE-FUNDED WARRANT. THE AGGREGATE GROSS PROCEEDS TO DISC FROM THIS OFFERING ARE EXPECTED TO BE APPROXIMATELY $225.5 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES, EXCLUDING THE EXERCISE OF ANY PRE-FUNDED WARRANTS. IN ADDITION, DISC HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL $33.825 MILLION OF SHARES OF ITS COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. ALL OF THE SECURITIES BEING SOLD IN THE OFFERING ARE BEING OFFERED BY DISC. THE OFFERING IS EXPECTED TO CLOSE ON JANUARY 24, 2025, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

DISC MEDICINE ANNOUNCES PRICING OF $225.5 MILLION UPSIZED PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

WATERTOWN, MASS., JAN. 21, 2025 (GLOBE NEWSWIRE) -- DISC MEDICINE, INC. (NASDAQ: IRON) (DISC), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF NOVEL TREATMENTS FOR PATIENTS SUFFERING FROM SERIOUS HEMATOLOGIC DISEASES, TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN OFFERING OF $200.0 MILLION OF SHARES OF ITS COMMON STOCK AND, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS THAT SO CHOOSE, PRE-FUNDED WARRANTS TO PURCHASE SHARES OF ITS COMMON STOCK. IN ADDITION, DISC INTENDS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL $30.0 MILLION OF SHARES OF ITS COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. ALL OF THE SECURITIES BEING SOLD IN THE PROPOSED OFFERING ARE BEING OFFERED BY DISC. THE PROPOSED OFFERING IS SUBJECT TO MARKET AND OTHER CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED, OR AS TO THE ACTUAL SIZE OR TERMS OF THE OFFERING.

Disc Medicine, Inc.

IRON

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Disc Medicine, Inc.

IRON.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

IRON